PLCB4 and prostate carcinoma: In human cancers, PLCB4 amplification has not been formally documented as a mechanism underlying overexpression, while it is provisionally catalogued in 20.6% of prostatic carcinomas exhibiting neuroendocrine phenotypes by the cBioPortal platform for cancer genomics [19].